Вектибикс (панитумумаб) – новое моноклональное антитело к рецепторам эпидермального фактора роста при лечении метастатического колоректального рака

1. Stephenson J, Cohn A, Crawford J et al. Administration of panitumumab (Pmab) every two weeks (Q2W) as a 30-min or 60-min infusion: safety and pharmacokinetics (PK) from a phase 1 study in patients with solid tumors. Gastrointestinal Cancers Symposium, Orlando, 2007; Abstr. 368.
2. Weiner L, Belldegrun A, Crawford J et al. Updated results from a dose and schedule study of Panitumumab (ABX-EGF) monotherapy in patients with advanced solid malignancies. Clin Cancer Res 2008; 14: 502–8.
3. Hecht J, Patnaik A, Berlin J et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 2007; 110: 980–7.
4. Hecht R, Mitchell E, Baranda J et al. Panitumumab (Pmab) efficacy in patients (pts) with metastatic colorectal cancer (mCRC) with low or undetectable levels of epidermal growth factor receptor (EGFr): Final efficacy and KRAS analyses. Gastrointestinal Cancers Symposium, Orlando, 2008; Poster 343.
5. Yoshino T, Muro K, Doi T et al. Phase 2 study of Panitumumab (Pmab)monotherapy in Japanese patients (pts) with metastatic colorectal cancer (mCRC) after the failure of fluoropyrimidine, irinotecan (CPT-11) and oxaliplatin (OHP) chemotherapy. Gastrointestinal Cancers Symposium, Orlando, 2008; Abstr. 366.
6. Van Cutsem E, Peeters M, Siena S et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658–64.
7. Amado R, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626–34.
8. Douillard J, Siena S, Cassidy J et al. Randomized Phase 3 Study of Panitumumab with FOLFOX4 vs FOLFOX4 Alone as First-line Treatment in Patients with Metastatic Colorectal Cancer: the PRIME Trial. Eur J Cancer 2009; 7(3 suppl): 10LBA.
9. Bokemeyer C, Bondarenko I, Hartmann J et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. J Clin Oncol 2008; 26: (suppl); abstr 4000.
10. Di Nicolantonio F, Martini M, Molinari F et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26: 5705–12.
11. Moroni M, Veronese S, Benvenuti S et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6: 279–86.
12. Humblet Y, Peeters M, Siena S et al. Association of skin toxicity (ST) severity with clinical outcomes and health-related quality of life (HRQoL) with panitunumab (Pmab). American Society of Clinical Oncology, Chicago, 2007; Abstr. 4038.
13. Peeters M, Price T, Hotko Y et al. Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment(tx) in patients(pts) with metastatic colorectal cancer (mCRC). Eur J Cancer 2009; 7(3 suppl): 14LBA.
14. Hecht J, Mitchell E, Chidiac T et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2008; 27: 672–80.
15. Punt C, Tol J, Rodenburg CJ et al. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol 2008; 26 (Suppl); abstr LBA4011.
16. Mitchell E, Lacouture M, Shearer H et al. Final STEPP results of prophylacatic versus reactive skin toxicity (ST) treatment (tx) for panitumumab (pmab)-related ST in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 2009; 27 (18 suppl); abstr CRA4027.

А.А.Трякин, С.А.Тюляндин

Отделение клинической фармакологии и химиотерапии РОНЦ им. Н.Н.Блохина РАМН, Москва